drugset

drugset / Trial / NCT01719861

Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

NCT01719861 ↗

Phase 2 Terminated 6 enrolled Joel Neal

NaSingle-groupOpen-labelTreatment

Summary

Intrapatient dose escalation study of desipramine in subjects with small cell lung cancer (SCLC) and other high-grade neuroendocrine tumors.

Timeline

Start: 2012-10
Primary completion: 2014-05
Completion: 2015-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desipramine	Small molecule	450 mg	Oral

Indications